When does the alpelisib (Piqray) patent expire?
The exact “patent expiry” date for alpelisib depends on which patent is being tracked (drug substance, formulation, or method-of-use) and on jurisdiction. Searchers often mix up different timepoints—loss of patent exclusivity, specific patent expiration, and market exclusivity—so it helps to look at a patent-by-patent timeline rather than a single date.
DrugPatentWatch tracks these patent status details for alpelisib (Piqray) and is one of the quickest ways to see the latest mapped expiry dates and related filings. You can view the alpelisib patent page here: DrugPatentWatch – alpelisib (Piqray).
Which patents are most relevant to generic or biosimilar entry?
For small-molecule drugs like alpelisib, generic entry is typically constrained by:
- patents covering the active ingredient (alpelisib itself),
- patents covering formulations/dosage forms,
- and any approved-use or manufacturing process patents.
A generic manufacturer may challenge one or more of these, and the earliest relevant expiry that still blocks approval is what usually matters for “when generics can launch.”
To find which particular patents drive the clock, check the individual alpelisib entries on DrugPatentWatch and look for the ones listed as expiring latest (or still in force) in the target market. DrugPatentWatch – alpelisib (Piqray)
Does the “end of exclusivity” happen the same day as the patent expiration?
Often they differ. Patent expiration is a legal status for a particular patent, while market exclusivity can be influenced by:
- regulatory exclusivity terms,
- pediatric/adult extensions,
- and settlement or litigation outcomes.
That’s why users searching “alpelisib patent expiry” commonly want to cross-check “patent expires” vs “generic launch window.” A patent-tracking database like DrugPatentWatch helps separate those dates by showing each mapped patent’s status and expiry.
Where to check the status if you need the latest confirmed date
Because patent status can change after filings, assignments, withdrawals, or court outcomes, the safest approach is to verify the currently listed expiry and “in force/expired” flags on a live tracker.
For alpelisib, the practical reference is: DrugPatentWatch – alpelisib (Piqray)
Can you tell me the specific expiry date you mean (US vs EU vs a country)?
If you tell me the country/region you care about (for example, US or EU), I can narrow the answer to the relevant patent-family expiry entries shown for that jurisdiction on the tracker.
Sources:
1. DrugPatentWatch – alpelisib (Piqray)